Back to search

Article

CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancers

2024-07-29

Abstract excerpt

Class 2 and 3 non-V600E BRAF mutations are oncogenic drivers in many cancer types. Currently, there are no established targeted therapies with proven efficacy for cancers with non-V600E BRAF mutations. We developed the investigator-initiated, Phase II BEAVER clinical trial ( NCT03839342 ) to evaluate the efficacy of BRAF and MEK inhibitors in patients with non-V600E BRAF mutations. The best objective response rate...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bd745200-8625-5b71-840f-e20c1c9ee79f
DOI
10.1101/2024.07.28.24311101
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancersDOI 10.1101/2024.07.28.24311101
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.Semantic proximity
Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumorsSemantic proximity
Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant TumorsSemantic proximity
The clinical, genomic, and transcriptomic landscape of BRAF mutant cancersSemantic proximity
Unraveling BRAF alterations: molecular insights to circumvent therapeutic resistance across cancer typesSemantic proximity
Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database.Semantic proximity
Targeting the multifaceted BRAF in cancer: New directions.Semantic proximity
Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancersSemantic proximity
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.Semantic proximity
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.Semantic proximity
Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination StrategiesSemantic proximity
Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity
Select a neighboring publication to make it the new centre.